CpG 684: an effective adjuvant for the inactivated COVID-19 vaccine in mice
Jiandong Liu1, Tianle Cang1, Congli Jiang2
1Beijing Minhai Biotechnology Co. Ltd, Beijing, 102600, China.
Aim:
This study used CpG 684 as adjuvant of inactivated COVID-19 vaccine to detect a humoral and cellular immune response in mice.
Materials & Methods:
We used 10 and 20 µg CpG 684 as adjuvants of an inactivated COVID-19 vaccine to immunize mice. IgG, IgG1, IgG2a, IgG2b and IgM binding antibodies were detected in serum by ELISA. The IFN-γ cytokine was detected by ELISPOT.
Results:
CpG 684 improved spike-specific IgG and IgM subtype binding antibodies and increased the neutralizing antibody titer against prototype, Delta and Beta strains. CpG 684 also improved cellular immune response.
Conclusion:
CpG 684 is an effective adjuvant for inactivated COVID-19 vaccine.
More Related Videos
07:04Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
Published on: September 16, 2018
05:44A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
Published on: December 9, 2022